Does Medicare have an implicit cost-effectiveness threshold? - Wikidata - wikimedia - TriplyDB

Does Medicare have an implicit cost-effectiveness threshold?

Does Medicare have an implicit cost-effectiveness threshold?

http://www.wikidata.org/entity/Q34121002

about

Randomized clinical trial of an emergency department observation syncope protocol versus routine inpatient admission.Economic analysis of nutrition interventions for chronic disease prevention: methods, research, and policy.Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States A decade of investment in infection prevention: a cost-effectiveness analysis Massachusetts Health Reform Cost Less and Was More Effective for Uninsured Individuals With Venous Thromboembolism: A Cost-Effectiveness Analysis.Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider.Cost-effectiveness of prospective red blood cell antigen matching to prevent alloimmunization among sickle cell patients.CHANGING FACE OF MEDICARE'S NATIONAL COVERAGE DETERMINATIONS FOR TECHNOLOGY.Economics of ramucirumab for metastatic colorectal cancer.The economic implications of broader sharing of liver allografts.What values do the public want their health care systems to use in evaluating technologies?The cost-effectiveness of drug regulation: the example of thorough QT/QTc studies.COST-EFFECTIVENESS IMPACTS CANCER CARE FUNDING DECISIONS IN BRITISH COLUMBIA, CANADA, EVIDENCE FROM 1998 TO 2008.Sustainability of behavioral interventions: beyond cost-effectiveness analysis.Cost-utility analysis of the housing and health intervention for homeless and unstably housed persons living with HIV.Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.Medicare and Amyloid PET Imaging: The Battle Over Evidence.How excluding some benefits from value assessment of new drugs impacts innovation.

P2860

Q33163526-8A8F32A0-8B0D-432C-B5EB-54B5565C8E27 Q35205894-236B97BC-37AE-4F5B-BFBA-94A25B783E77 Q35606843-F360EB29-9401-472B-9F1E-EF2542EFA6B8 Q35619161-883C2F57-39E5-460D-9154-34A1586E9D67 Q36549876-E0C01C78-8180-41F7-9C03-292A2BEB8E6D Q36803506-2F052505-EFF1-4B71-BAA6-16E3374A4364 Q36968664-8E3E2B24-091B-4F13-A6BC-83D1B1B14DBB Q37136211-AC777FDE-EADB-4E15-8673-EDEAFFC4B792 Q38691855-00E89DDC-651F-4F6F-B8AC-01A416D975A5 Q39003764-8EA29EF8-EBB5-451F-A75B-6FC325D4A70B Q42694182-876C0006-8E64-4BE0-8BC5-E54CFA09EC25 Q42767132-62AB4CA5-0DA2-4CCD-8266-9FF29DC6B59D Q45948688-565C6C1A-2122-48C4-A638-5323C9EA5230 Q46230521-C4EE352D-0A49-436E-9C38-6F419F63A587 Q46668821-C16C946E-8DFE-45C4-8F38-09E02016442F Q47760217-83E4B343-26F7-4D81-88B0-E2A122E96D16 Q50899665-980B1F39-7904-49F4-9A7E-B28F8344FCFA Q52982412-CF50107B-C8EE-4E47-80EE-5B42B4F1C765 Q53328388-A216D731-5FF4-42A5-A23E-C6D8E3E86728

P2860

Does Medicare have an implicit cost-effectiveness threshold?

http://www.wikidata.org/entity/Q34121002

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Does Medicare have an implicit cost-effectiveness threshold?

@ast

Does Medicare have an implicit cost-effectiveness threshold?

@en

Does Medicare have an implicit cost-effectiveness threshold?

@nl

type

label

Does Medicare have an implicit cost-effectiveness threshold?

@ast

Does Medicare have an implicit cost-effectiveness threshold?

@en

Does Medicare have an implicit cost-effectiveness threshold?

@nl

prefLabel

Does Medicare have an implicit cost-effectiveness threshold?

@ast

Does Medicare have an implicit cost-effectiveness threshold?

@en

Does Medicare have an implicit cost-effectiveness threshold?

@nl

P1433

Q34121002-5DD1FC82-83D3-4B50-821F-A3C15F392166

P1476

Q34121002-7FC4383B-B7B9-4265-9D26-A1DC2CB270A7

P2093

Q34121002-7FCF2E96-2262-4EC2-AC7C-D1EF41EB0E78

Q34121002-849BC27E-DDF0-480C-9F18-997D975DDA5A

Q34121002-944E3BD0-820F-493B-A981-786B7D8801DC

P2860

Q34121002-09660753-5E63-4F4B-A24C-28EECC842E43

Q34121002-120A5763-C3AE-40A9-A00F-CD81135D5025

Q34121002-1D92DB64-C52B-43BD-B3FF-A43E8528E50E

Q34121002-22E41AAB-9E10-4AF6-B277-303D7E9CD8F8

Q34121002-2EF6FD2F-975A-47F6-9C7C-4ED5D4FF27D3

Q34121002-3782E0D4-D971-43AC-9129-039B803A9297

Q34121002-440ACE2E-E9EE-4F2B-9206-A563C0D15845

Q34121002-44C17A6F-24FA-4319-8D27-8019E6A84ECD

Q34121002-4906E0BE-907A-4AB7-9985-E6842F694253

Q34121002-4E14B3DE-ECD7-430C-8877-39324637B6CE

P304

Q34121002-3D80A644-91E7-43B2-AE9C-AD5BA3312732

P31

Q34121002-7C74B1A3-0243-4700-8707-B098AFB99B70

P356

Q34121002-7B8C027F-4629-4015-BB49-B22D0F69EB93

P433

Q34121002-BE3C5BEB-7A05-42C5-B5D5-3CE064C45595

P478

Q34121002-6BC14CC8-2719-4E41-B339-2ECCA33E6F7A

P577

Q34121002-4BE05E60-A2E4-46F5-909E-A004AB987580

P5875

Q34121002-A3A1961B-88E2-4801-ACD7-C2F318CAD64B

P698

Q34121002-741DECC1-73D9-402D-AA20-0519B534EBF6

P356

0272989X10371134

P1433

Medical Decision Making

P1476

Does Medicare have an implicit cost-effectiveness threshold?

@en

P2093

James D Chambers

http://www.w3.org/2001/XMLSchema#string

Martin J Buxton

http://www.w3.org/2001/XMLSchema#string

Peter J Neumann

http://www.w3.org/2001/XMLSchema#string

P2860

Bias in published cost effectiveness studies: systematic review.

A UK trial-based cost--utility analysis of transmyocardial laser revascularization compared to continued medical therapy for treatment of refractory angina pectoris.

CMS's landmark decision on CT colonography--examining the relevant data.

Are pharmaceuticals cost-effective? A review of the evidence.

Development of WHO guidelines on generalized cost-effectiveness analysis.

Is technological change in medicine worth it?

Cost-effectiveness of implantable cardioverter-defibrillators.

Medicare and cost-effectiveness analysis.

The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the N0 neck.

Impact of cochlear implants on the functional health status of older adults.

P304

E14-27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0272989X10371134

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44676469

http://www.w3.org/2001/XMLSchema#string

P698

20551473

http://www.w3.org/2001/XMLSchema#string